Observational studyHuman vaccines & immunotherapeutics2024
Efficacy of HBV booster dose administration in Italian medical students in relation to health determinants.
Observational study in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the efficacy of a booster dose of HBV in Italian medical students. We conducted a prospective observational study in students who had received a full course of anti-HBV vaccination for at least 15 y. Those with an anti-HBs titer <10 mIU/mL were offered a booster dose of the HBV vaccine and the antibody titer was reevaluated after 1 month. The participants were classified into three categories: with anti-HBs titer >100 mIU/mL, between 10 and 100 mIU/mL and <10 mIU/mL. The study population was n. 625 medical student and 355 (56.8%) with anti HBs titer <10 mIU/mL were offered a booster dose. A total of 166 of them received the booster dose and 92.77% (38 + 116/166) achieved an anti-HBs titer ≥10 mIU/mL. The post-booster anti-HBs titer response was higher, i.e. >100 mIU/mL, in subjects who had a pre-booster anti-HBs titer between 1.00 and 9.99 mIU/mL (84.38%, 81/96), compared to those with titer <1 mIU/mL (50.00%, 35/70). Subjects with a titer <1.00 mIU/mL at enrollment showed no anamnestic response (post-booster anti-HBs <10 mIU/mL, RRR 0.23, 95% CI 0.06-0.84) and to a low anamnestic response (post-booster anti-HBs 10-100 mIU/mL, RRR 0.16, 95% CI 0.07-0.38). Physical activity was linked to a better antibody response to vaccination (post-booster anti-HBs 10-100 mIU/mL: RRR 2.39, 95% CI 1.05-5.59). Immune protection following primary vaccination against HBV tends to wane over time. Booster dose induces anamnestic responses, especially in individuals who maintain titer HBsAg >1 mIU/mL and do physical activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.